BIO applauds the SEC for finalizing provision of the Jumpstart Our Business Startups Act that will raise offering ceiling under Reg A+ from $5 million to $50 million. According to BIO President and CEO Jim Greenwood, most small biotech companies operate without any product revenue, relying on external investors to finance all of their operations. Increased offering limit under Reg A+ will enable emerging biotech companies to raise capital while reducing regulatory compliance.